Latest News and Press Releases

Garching / Munich, February 18, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Raymond James Private Biotech...

Garching / Munich, February 7, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in Oppenheimer’s 35th Annual Healthcare...

Phase 3 clinical trial with ITM-11 met its primary endpoint, demonstrating clinically relevant and statistically significant benefit in Progression-Free Survival (PFS) compared to everolimusITM plans...

Garching / Munich / Berlin, Germany, January 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Ariceum Therapeutics (Ariceum), a private biotech...

Garching / Munich, Germany, December 13, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that its Chief Executive Officer, Dr. Andrew...

Garching / Munich, November 11, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry investor...

Neufahrn / Garching / München, 24. Oktober 2024 – ITM Isotope Technologies Munich SE (ITM), ein führendes radiopharmazeutisches Unternehmen, die Technische Universität München (TUM) und das TUM...

Neufahrn / Garching / Munich, Germany, October 24, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, the Technical University of Munich (TUM) and the TUM...

  Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a. 177Lu)Companies enter into an additional manufacturing and supply...

Garching / Munich, September 19, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry...